India Exchange Filings

Alembic Pharmaceuticals Binimetinib Approval

Alembic Pharmaceuticals Ltd receives USFDA final approval for generic Binimetinib Tablets, with 180-day exclusivity eligibility

  • Approved strengths: 15 mg and 45 mg; therapeutically equivalent to Mektovi.
  • Used with encorafenib for specified patients with BRAF-mutated melanoma and metastatic non-small cell lung cancer.
  • IQVIA estimates US sales of US$282 million for the 12 months ended September 2026.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.